ATE374214T1 - Monoklonaler anti-cd-40-antikörper - Google Patents
Monoklonaler anti-cd-40-antikörperInfo
- Publication number
- ATE374214T1 ATE374214T1 AT02720634T AT02720634T ATE374214T1 AT E374214 T1 ATE374214 T1 AT E374214T1 AT 02720634 T AT02720634 T AT 02720634T AT 02720634 T AT02720634 T AT 02720634T AT E374214 T1 ATE374214 T1 AT E374214T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- monoclonal anti
- agonistically
- antagonistically
- acting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/013672 WO2001083755A2 (en) | 2000-04-28 | 2001-04-27 | Human anti-cd40 antibodies and methods of making and using same |
US09/844,684 US7063845B2 (en) | 2000-04-28 | 2001-04-27 | Human anti-CD40 antibodies |
JP2001142482 | 2001-05-11 | ||
JP2001310535 | 2001-10-05 | ||
US10/040,244 US20030059427A1 (en) | 2000-04-28 | 2001-10-26 | Isolation and characterization of highly active anti-CD40 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE374214T1 true ATE374214T1 (de) | 2007-10-15 |
Family
ID=32601004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02720634T ATE374214T1 (de) | 2001-04-27 | 2002-04-26 | Monoklonaler anti-cd-40-antikörper |
Country Status (8)
Country | Link |
---|---|
US (4) | US7193064B2 (de) |
EP (2) | EP2009027B1 (de) |
CN (1) | CN101508734A (de) |
AT (1) | ATE374214T1 (de) |
AU (1) | AU2009200017A1 (de) |
CA (1) | CA2658221C (de) |
DK (1) | DK1391464T3 (de) |
PT (1) | PT1391464E (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
EP2009027B1 (de) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Monoklonaler Antikörper gegen CD40 |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
JP4680902B2 (ja) * | 2003-07-22 | 2011-05-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Rg1抗体及びその使用 |
US7871610B2 (en) * | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
AU2004266242A1 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
TW200540186A (en) * | 2003-12-25 | 2005-12-16 | Kirin Brewery | Mutants of anti-CD40 antibody |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
US8911726B2 (en) * | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
DK1889065T3 (da) | 2005-05-18 | 2013-09-02 | Xoma Technology Ltd | Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent |
UA94060C2 (ru) * | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Моноклональное антитело, которое специфически связывает alk-1 |
MEP39508A (en) | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
MX2008013993A (es) * | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
MX2009005776A (es) | 2006-12-01 | 2009-06-10 | Medarex Inc | Anticuerpos humanos que se enlazan al cd 22 y sus usos. |
WO2008089070A2 (en) * | 2007-01-12 | 2008-07-24 | Dyax Corp. | Combination therapy for the treatment of cancer |
US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
AU2010222929B2 (en) * | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
DK2406289T3 (en) * | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
US9562104B2 (en) | 2009-03-10 | 2017-02-07 | Baylor Research Institute | Anti-CD40 antibodies |
BR112012008665A2 (pt) | 2009-10-12 | 2016-11-22 | Pfizer | tratamento de câncer |
HUE038788T2 (hu) * | 2010-03-31 | 2018-11-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CN103347898B (zh) * | 2011-01-10 | 2017-12-05 | Ct大西洋有限公司 | 包括与肿瘤相关抗原结合抗体的联合治疗 |
PT2683406T (pt) * | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e utilização dos mesmos |
EP2699598B1 (de) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs |
EP3508500A1 (de) | 2011-04-29 | 2019-07-10 | Apexigen, Inc. | Anti-cd40-antikörper und verfahren zur verwendung |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
GB201316644D0 (en) * | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
GB201322583D0 (en) | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
AU2015204503B2 (en) | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
US20160015803A1 (en) * | 2014-07-18 | 2016-01-21 | Ross Kedl | Immunostimulatory combinations and use thereof |
MX2017001864A (es) | 2014-08-12 | 2017-08-02 | Alligator Bioscience Ab | Tratamientos conjuntos con anticuerpos anti cd40. |
SG11201702598XA (en) | 2014-10-29 | 2017-05-30 | Seattle Genetics Inc | Dosage and administration of non-fucosylated anti-cd40 antibodies |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
PT3240801T (pt) | 2014-12-31 | 2021-02-18 | Checkmate Pharmaceuticals Inc | Imunoterapia antitumoral combinada |
HUE048284T2 (hu) * | 2015-05-29 | 2020-07-28 | Abbvie Inc | Anti-CD40 antitestek és alkalmazásuk |
CN116063481A (zh) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
CN109069622A (zh) | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | 特异性结合人cd40的拮抗性抗体和使用方法 |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
CN109069627A (zh) * | 2016-01-14 | 2018-12-21 | 纪念斯隆-凯特琳癌症中心 | 对foxp3衍生肽特异性的t细胞受体样抗体 |
WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
US20180164221A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
BR112019022356A2 (pt) | 2017-04-27 | 2020-05-26 | Juno Therapeutics Gmbh | Reagentes de partícula oligoméricos e métodos de uso dos mesmos |
MX2019014375A (es) | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. |
WO2019057792A1 (en) * | 2017-09-19 | 2019-03-28 | Mab Discovery Gmbh | CD40 ANTIBODY AGONISTS |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
CA3090652A1 (en) | 2018-02-06 | 2019-08-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
US20210179727A1 (en) * | 2018-04-20 | 2021-06-17 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
EP3806848A2 (de) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Erhöhung der immunaktivität durch modulation von postzellulären signalisierungsfaktoren |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
KR20210070317A (ko) | 2018-09-28 | 2021-06-14 | 리브젠 바이오파마 코., 엘티디. | 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도 |
WO2020070288A1 (en) | 2018-10-05 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
TW202039558A (zh) * | 2018-11-30 | 2020-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗cd40抗體、其抗原結合片段及其醫藥用途 |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
CN112409486B (zh) * | 2020-11-26 | 2022-05-20 | 杭州百凌生物科技有限公司 | 一种抗cd40抗体及其应用 |
JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
CN115403670A (zh) | 2021-05-26 | 2022-11-29 | 安徽瀚海博兴生物技术有限公司 | 抗cd40抗体及其用途 |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023020475A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd40-targetting antibodies and uses thereof |
CN117500816A (zh) | 2021-08-26 | 2024-02-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024401A (en) | 1975-11-17 | 1977-05-17 | General Electric Company | X-ray apparatus |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
EP0434879A1 (de) | 1989-12-14 | 1991-07-03 | Schering-Plough | Verfahren zur Herstellung von faktorabhÀ¤ngigen menschlichen B-Zellinien |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2125396A1 (en) | 1991-12-10 | 1993-06-24 | Wayne A. Marasco | Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof |
EP0651797B1 (de) | 1992-07-09 | 2004-01-28 | Chiron Corporation | Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
KR960704576A (ko) * | 1993-10-01 | 1996-10-09 | 크리스토퍼 엘. 와이트 | CD40에 대한 항체(Antibodies to CD40) |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (de) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Menschliche antikörper aus xenomäusen |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
DE69841452D1 (de) | 1997-02-28 | 2010-03-04 | Kyowa Hakko Kirin Co Ltd | Humanes Chromosomfragment und ein Vektor, der dies enthält |
CA2319448A1 (en) | 1998-02-04 | 1999-08-12 | The General Hospital Corporation | Costimulatory blockade and mixed chimerism in allotransplantation |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
JP2002512776A (ja) | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
IL139601A0 (en) | 1998-05-26 | 2002-02-10 | Genitrix Llc | Compositions and methods of modulating an immune response to an antigen |
WO2000000156A2 (en) | 1998-06-26 | 2000-01-06 | Trustees Of Dartmouth College | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US6482411B1 (en) * | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
WO2001024823A1 (en) | 1999-10-04 | 2001-04-12 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
JP2001142482A (ja) | 1999-11-10 | 2001-05-25 | Nippon Hoso Kyokai <Nhk> | 音声字幕化装置 |
WO2001056603A1 (en) | 2000-02-01 | 2001-08-09 | Tanox, Inc. | Cd40-binding apc-activating molecules |
JP2001310535A (ja) | 2000-04-28 | 2001-11-06 | Canon Inc | 記録装置、および記録ヘッドの濃度むら補正方法 |
US7063845B2 (en) * | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
JP4271440B2 (ja) | 2000-10-02 | 2009-06-03 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | ヒト抗cd40抗体 |
EP2009027B1 (de) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Monoklonaler Antikörper gegen CD40 |
WO2003029296A1 (en) | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US6933292B2 (en) | 2002-07-30 | 2005-08-23 | Children's Medical Center Corporation | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
-
2002
- 2002-04-26 EP EP08017499.8A patent/EP2009027B1/de not_active Expired - Lifetime
- 2002-04-26 EP EP08017500A patent/EP2011802A3/de not_active Withdrawn
- 2002-04-26 CA CA2658221A patent/CA2658221C/en not_active Expired - Lifetime
- 2002-04-26 PT PT02720634T patent/PT1391464E/pt unknown
- 2002-04-26 AT AT02720634T patent/ATE374214T1/de active
- 2002-04-26 CN CNA2008101609045A patent/CN101508734A/zh active Pending
- 2002-04-26 DK DK02720634T patent/DK1391464T3/da active
-
2003
- 2003-10-23 US US10/693,629 patent/US7193064B2/en not_active Expired - Lifetime
-
2006
- 2006-12-05 US US11/633,716 patent/US7537763B2/en not_active Expired - Lifetime
-
2008
- 2008-10-06 US US12/246,325 patent/US20090123466A1/en not_active Abandoned
-
2009
- 2009-01-02 AU AU2009200017A patent/AU2009200017A1/en not_active Withdrawn
-
2010
- 2010-03-23 US US12/729,997 patent/US20100234578A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2009027A1 (de) | 2008-12-31 |
US20090123466A1 (en) | 2009-05-14 |
CA2658221A1 (en) | 2002-11-07 |
DK1391464T3 (da) | 2008-01-14 |
US20070077242A1 (en) | 2007-04-05 |
EP2009027B1 (de) | 2014-05-21 |
EP2011802A3 (de) | 2009-04-15 |
US20100234578A1 (en) | 2010-09-16 |
AU2009200017A1 (en) | 2009-02-05 |
US7537763B2 (en) | 2009-05-26 |
CN101508734A (zh) | 2009-08-19 |
US7193064B2 (en) | 2007-03-20 |
PT1391464E (pt) | 2007-11-15 |
EP2011802A2 (de) | 2009-01-07 |
US20040120948A1 (en) | 2004-06-24 |
CA2658221C (en) | 2012-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE374214T1 (de) | Monoklonaler anti-cd-40-antikörper | |
EP1914243A3 (de) | Monoglonaler Antikörper gegen CD40 | |
NO20040925L (no) | Flat belysningsanordning. | |
NO20042474L (no) | Reguleringsventil-stromningsjusteringsanordning. | |
NO20040671D0 (no) | Emballasje for myke, engangs-kontaktlinser. | |
NO20041165L (no) | Avstengningsanordning. | |
BR0215188B1 (pt) | válvula de gaveta. | |
ITTO20020003A1 (it) | Dispositivo di verifica per veicolo. | |
ITPD20020236A1 (it) | Dispositivo di regolazione a manopola, particolarmente | |
BR0116998B1 (pt) | dispositivo osteossintético. | |
BR0204689B1 (pt) | dispositivo de fixação. | |
ITTO20020085U1 (it) | Proiettore per veicoli. | |
ITTO20010754A0 (it) | Dispositivo di regolazione della posizione di un pedale. | |
ES1049393Y (es) | Dispositivo de ambientacion olorosa multiple. | |
ITTO20020066V0 (it) | Proiettore per veicoli. | |
ES1050791Y (es) | Dispositivo de control funcional para cafeteras de hosteleria. | |
ITTO20020067V0 (it) | Proiettore per veicoli. | |
ES1050837Y (es) | Un dispositivo de union. | |
ES1049284Y (es) | Dispositivo de cierre antivandalico. | |
ES1050767Y (es) | Dispositivo higienico-sanitario. | |
ES1049664Y (es) | Dispositivo autohinchador. | |
ES1051818Y (es) | Fuente. | |
ITRE20010020V0 (it) | Dispositivo collimatore. | |
ES1050793Y (es) | Dispositivo de fijacion de luminarias. | |
ITBO20020537A1 (it) | Dispositivo valvolare. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1391464 Country of ref document: EP |
|
EEIH | Change in the person of patent owner |